Memantine (Axura)
Memantine is the first and only representative of a new class of Alzheimer drugs ... New Memantine Literature. Brief Profile. Product characteristics. Mode of Action ...
memantine.com - Mode of Action
Mode of Action. Memantine as an NMDA receptor antagonist can prevent the pathological ... Mode of action of memantine (Interactive animation) ...
Memantine - Wikipedia, the free encyclopedia
Memantine agonist action at dopamine D2High receptors" ... The molecular basis of memantine action in Alzheimer's disease and other ...
Memantine: Information from Answers.com
Memantine Memantine is a new drug for treating Alzheimer's disease, mental ... The molecular basis of memantine action in Alzheimer's disease and other ...
Namenda (Memantine), Alzheimer's medication
Namenda (Memantine)is a medication used in the treatment ... Mechanism of Action and ... Memantine is postulated to exert its therapeutic effect through ...
FDA Approves Alzheimer's Drug
The entry page to Global Action on Aging's Web site. ... and blocking its action may explain Memantine's benefits, Ferris said. ...
Memantine - SciTopics
Author: Wojciech Danysz, Title: Memantine, Date: 13 August 2008, Publisher: SciTopics ... ( Fig.1: Memantine chemical structure) Mechanism of action. ...
Memantine - Pubdrug
2 Mechanism of Action. 3 Time Required for Therapeutic ... causing a similar action to that of magnesium, though memantine stays in the channel longer. ...
Memantine
Memantine is postulated to exert its therapeutic effect ... For the treatment of moderate to severe dementia of the Alzheimer's type. Mechanism Of Action: ...
Welcome to memantine-chat.com! - Axura -
Memantine is the first and only representative of a new class of Alzheimer drugs ... New Memantine Literature. Brief Profile. Product characteristics. Mode of Action ...
|
BiomedExperts: Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease--a unified glutamatergic hypothesis on the mechanism of action.
The involvement of glutamate mediated neurotoxicity in the pathogenesis of Alzheimer's disease is finding increasingly more acceptance in the scientific community. Central to this hypothesis is the assumption that in particular glutamate receptors of the N-methyl-D-aspartate (NMDA) type are overactivated in a tonic rather than a phasic manner. Such continuous mild activation leads under chronic conditions to neuronal damage. Moreover, one should consider that impairment of plasticity (learning) may result not only from neuronal damage per se but also from continuous activation of NMDA receptors.